My guest this week is James Lanthier, CEO of Mindset Pharma of Toronto, Canada, a company that is seeking to develop novel psychedelic analogues to existing psychedelics such as psilocybin, DMT, and 5-MeO-DMT for more targeted delivery, efficacy, and therapeutic potential for use in the developing psychedelic healthcare field. You can find them online at www.mindsetpharma.com
